Tanios S. Bekaii-Saab, MD, professor of medicine and director of the GI oncology program at the Mayo Clinic (Phoenix, AZ), joins the show to highlight the research with significant clinical application presented at the virtual ASCO-GI meeting, including KEYNOTE-177 and ATOMIC in colorectal cancer, atezolizumab plus bevacizumab for first-line HCC, a survival update in the POLO trial and utility of radiation for pancreatic cancer, PD-1 inhibitors for first-line and adjuvant treatment of gastric cancer, and much more.
Learn more about our guest here: https://www.mayo.edu/research/faculty/bekaii-saab-tanios-s-m-d/bio-20396570
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
